Alder BioPharma (ALDR): Far from Game Over But Cutting PT - Jefferies

November 22, 2016 7:08 AM EST
Get Alerts ALDR Hot Sheet
Price: $21.55 -4.65%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 23 | Down: 34 | New: 34
Trade ALDR Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Alder Biopharm (NASDAQ: ALDR) but cut his price target to $46 from $57 after additional details emerged that indicate Teva Pharmaceutical's (NYSE: TEVA) amended broad CGRP claims were upheld at Fri's EPO hearing. This is a surprise, which could potentially block Alder's '403 from the EU mkt.

However, there are reasons Alder could reverse this on appeal, FTO in much larger U.S. mkt is likely unaffected (with worst case likely just royalties to TEVA), and stock already likely reflects this level as the news spread quickly. The price target is cut on reduced EU POS but the analyst still sees upside opportunity.

For an analyst ratings summary and ratings history on Alder Biopharm click here. For more ratings news on Alder Biopharm click here.

Shares of Alder Biopharm closed at $26.45 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment